Seeking Alpha • Mar 04

Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value

Summary Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show simufilam's potential in treating TSC-related seizures, but translating these results to human efficacy remains uncertain. Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead to shareholder dilution. Despite strategic moves, Cassava remains a "sell" due to high risks, competition, and the need for significant clinical validation. Read the full article on Seeking Alpha

Seeking Alpha • Nov 07

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Summary Cassava Sciences' stock has declined significantly since its peak, with ongoing skepticism about the efficacy of its Alzheimer's drug, simufilam. Phase 3 trial results for simufilam are anticipated by year-end, which could either validate or disprove its effectiveness. Cassava has faced legal and scientific scrutiny, with key figures resigning and the company settling a $40m SEC penalty. The new CEO remains cautiously optimistic but acknowledges the potential for ambiguous results and the need for further FDA consultations. Read the full article on Seeking Alpha

Seeking Alpha • Jul 24

Cassava Sciences: Turning The Corner Into A Brick Wall

Summary Cassava Sciences' mechanism of action for simufilam has not been independently verified. Simufilam only slows down the progression of solidly mild Alzheimer's disease for one year; it does not stablize mild Alzheimer's disease for two years as the company claims. The FDA is unlikely to approve another drug with limited short-term effectiveness, especially one which while safe is surrounded by so much controversy. Read the full article on Seeking Alpha

分析記事 • Oct 17

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Jul 04

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

分析記事 • Mar 05

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Nov 19

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Oct 13

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences (NASDAQ:SAVA) has begun an open-label extension study of its Alzheimer's disease candidate simufilam that will last a year. The trial is expected to enroll ~1.6K participants. Enrollment is set to begin in November. The study is for participants that have completed one of the company's two phase 3 trials. They will be given 100 mg simufilam twice daily. Seeking Alpha contributor Biotech Beast views Cassava Sciences (SAVA) as a strong sell as there is still a great deal of uncertainty hanging over the stock.

Seeking Alpha • Sep 29

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Summary This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science. There have been several recent positive developments. The data readouts will be massive catalysts. This is such a binary investment you will either do very well, or be left holding the bag. It has been quite some time since we checked on the very volatile and controversial Cassava Sciences (SAVA). At last check, we felt this was going to remain one of the most controversial and volatile stocks as we had into 2022. We are ultimately bullish on the science, but the stock action has been akin to gambling. The stock got pushed down hard this year as a number of questions regarding the research and business practices were raised. The thing is that this stock can make you some really fast gains on both the long and short side of the trade. However, we see the potential for multiple orders of gains should the science hold up here. In other words, it makes a great swing trading stock, but for the medium/long term, you are essentially buying a possible play that could see 5-10X gains, or be worthless, all depending on the science and how it plays out. The science called into question The science has been getting called into question for over a year. That has impacted the crazy volatility even further, and is why it is one of those stocks that lead many to consider Wall Street a casino. The ultimate question is can their drug, simufilam, designed to treat Alzheimer's disease work? We are hoping for humanity's sake that one of the companies working on this type of treatment finds success. Alzheimer's is a horrible affliction and has impacted many of our lives in some capacity or another. So there is a lot of hope with these research candidates under study, such as simufilam, for those suffering from Alzheimer's as well as their loved ones. There just are not effective treatments on the market. That said, the initial data readouts have been positive, but have been met with extreme criticism. You may recall that the interim analysis demonstrated a 1.6 point improvement in the ADAS-Cog11 system in Alzheimer's patient's cognition level rating. So what? Well as it turns out, that is a 10% average improvement. The readout also showed that there was a near 30% improvement in behaviors such as agitation and fear. Those were good results. The constant mantra has been that the company has falsified and manipulated data to make the drug look better. This has cast a cloud on the company and shares have suffered for months. But things are looking up. Some positive developments There has been some insider buying as well. A director, Richard Barry, bought 36.16K shares of common stock at $23.79 on Aug. 23 for $860K. This was an increase in the position of nearly 20% and Barry now has ownership of 186,159 shares. The stock has almost doubled since then. Volumes are up the last month, but the most beneficial news was the recent clearing by one medical journal of the company doing anything wrong in terms of data manipulation. The company has been accused of research misconduct by several entities. There continue to be bears putting their faith in accusations of some possible misdealings related to data collection and reporting. Last year we saw scientific victory, in The Journal of Neuroscience. In that review by the Journal of Neuroscience, an investigation and critical review showed no evidence of data manipulation in one of the technical papers that was an early key to effectiveness of simufilam. Back in 2012 when the drug was first being looked at for possible effectiveness, the accusations from the group claimed the data was manipulated and false. The company responded saying these allegations were false. Essentially they claimed the western blots, which measure proteins and changes, were falsified. Recently the Neuroscience journal reviewed data, and there is once again "no evidence to support claims of data manipulation in a 2005 paper" authored by the company and its scientific collaborators. This summer a scientist called into question foundational research on amyloid plaque theory, as basis for simufilam's target work. Then just a few weeks ago, the journal had cleared the company of scientific misconduct. Then, with little coverage surprisingly, the SEC which was investigating the company also concluded that they recommend closing their investigation. This work was covered in great detail by fellow contributor Jacob Braun. With the huge short interest in the stock, trading has been wild and the stock has rallied. Needless to say, it has been a journey. But the company is not out of the woods entirely. Cassava is still awaiting the results of an investigation from The City University of New York on one of its own researchers who published positive results on simufilam that has come under some of the same data related scrutiny. There is also controversy after the company was accused of being investigated by the Justice Department, something the company denied vehemently. Looking ahead As we look ahead, the company has enough cash to fund operations for at least two more years. It has nearly $200 million in cash and absolutely no debt. The company spends anywhere from $15-$25 million a quarter (more when trials underway, and being set up), so that is at least two years of funding. We believe that with pending data readouts, the investment thesis will have played out by then, as the drug will likely be considered successful or a failure. It may even be approved.

Seeking Alpha • Sep 21

Cassava Sciences: Trying To Manage Expectations

Summary The second group of patients on simufilam on average experienced a .2 point decline in ADAS-Cog scores after one year. These results are similar to acetylcholinesterase inhibitors for mild Alzheimer's disease. Critics claim that some individuals in the first group who experienced a mean improvement of 3.2 did not have Alzheimer's, whereas supporters claim this is true for the second group. Accurate MMSE numbers for both groups would add more clarity to the situation. The apparent mechanisms of action for simufilam suggest that further decline from baseline is likely. An explanation is needed as to why the first group of fifty trial participants on Cassava Sciences' (SAVA) simufilam experienced a 3.2 improvement in ADAS-Cog scores while the second group experienced a .2 point decline. Critics have asserted that at least some of those in the first group did not have Alzheimer's disease. Cassava Sciences advocates apparently taking their cue from the company now have tried to flip the script by arguing that some in the second group did not have Alzheimer's disease but instead had some other form of dementia or mixed dementia, such as Alzheimer's disease and vascular dementia. That is why they did not perform as well. It is impossible to resolve this controversy with the data at hand, but there are clues to a possible answer. According to Cassava Sciences, the first group had a mean ADAS-cog score of 15.5 and a mean MMSE score of 22.1, but a mean ADAS-cog score of 15.5 corresponds to a mean MMSE score of 25.5 (table one). An MMSE score of between 21 and 24 is usually indicative of mild Alzheimer's disease. Some of those with higher MMSE scores in the first group may have been allowed into the trial based on being amyloid positive. But being amyloid positive is not the same thing as having Alzheimer's disease. Individuals with strong antioxidant levels in their brain can have significant amounts of amyloid and not have Alzheimer's disease (study). It is likely, then, that some people in the first group had mild cognitive impairment, very early Alzheimer's disease, or were cognitively normal. The results from the second group of 50 patients are even more difficult to interpret because there is no public record of their baseline scores and characteristics: MMSE scores, ADAS-cog scores, age, gender, ethnicity, APOE4 status, etc. Nothing. The contention made by some of the company's backers is that some individuals in this group did not go under intensive testing to determine if they had Alzheimer's disease. If that is the case, then some participants were admitted into the trial based solely on their MMSE scores. Just like amyloid, MMSE scores alone cannot be used to provide a definitive diagnosis of Alzheimer's disease. So it is possible that a few of these individuals had either some other form of dementia or mixed dementia. But even if this is the case, treatments that lessen oxidative stress in Alzheimer's disease are likely to have at least some benefits in terms of cognition for those with other forms of dementia (possibility). Knowing the actual MMSE scores of the trial participants in both groups would not completely resolve this debate, but it would go a long way in that direction. If there is a significant gap in terms of baseline MMSE scores between the two groups, this would strongly indicate (but not prove) that more people in the second group had mild Alzheimer's disease than in the first group. If the .2 point decline is reflective of the effects of simufilam for mild Alzheimer's disease, this would put it right in line with acetylcholinesterase inhibitors for mild Alzheimer's disease (chart). And this may be no accident. Acetylcholinesterase inhibitors such as Aricept inhibit oxidative stress as sigma-1 agonists and are peroxynitrite decomposition catalysts (a nitro-oxidant that probably plays a key role in Alzheimer's disease). Simufilam potentially at least can do the same (previous article). About 20 percent of the population does not have a functioning sigma-1 receptor, so they do not benefit from this form of treatment. Sigma-1 receptor activity declines with the progression of Alzheimer's disease, so this type of treatment does not work nearly as well for moderate Alzheimer's disease as it does for mild Alzheimer's disease. This may explain why some participants responded better to simufilam than others. Not only the results but probably the mechanism of action of simufilam is in need of adjustment. Cassava Sciences has always presented itself outside the realm of various other anti-amyloid treatments, but it too is an amyloid-centric approach. The company's stated mechanism of action is that by restoring filamin A to its normal configuration, it reduces amyloid toxicity by "disabling its signalling" via nicotinic acetylcholine and toll-like receptors (publication). Yet, in trials where nearly all amyloid was removed, Alzheimer's disease continues to progress. It does not take a very small amount of amyloid to contribute to Alzheimer's disease, it requires a lot (such as the case with APOE4 carriers). In non-APOE4 carriers who have less amyloid, anti-amyloid drugs don't work at all (latest example from Eli Lilly). It is possible that simufilam produces beneficial results even in the absence of amyloid. For instance, simufilam may be a zinc and copper chelator, which may be of some significance in that zinc and copper contribute to the misfolding of proteins as well as to their toxicity. If this is the case, then it is the presence of copper and zinc and not any particular misfolded protein that can at least early on contribute to the progression of Alzheimer's disease. Eventually, though, copper and zinc are entombed in amyloid plaques, so their role in Alzheimer's disease declines. It is possible, though, that a small part of simufilam's early benefit is as a copper and zinc chelator. The role of misfolded proteins by themselves in Alzheimer's disease is somewhat uncertain. Misfolded amyloid by itself probably does no damage to the brain. Misfolded tau proteins can inhibit neurotransmissions. It is unclear at this point if misfolded filamin A proteins do any damage to the brain or not.

Seeking Alpha • Sep 09

Cassava Sciences reaches over five-month high on rising volumes

After a sharp selloff early this year, clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) appears to be turning the tide, with its shares rising for the fourth straight session Friday on above-average volume to reach the highest level since April. Nearly 2.9M SAVA shares have changed hands so far, compared to the 65-day average of ~2.4M. The upsurge comes as SAVA, a developer of an Alzheimer’s therapy, is set to participate in an investor conference organized by H.C. Wainwright next week. SAVA stock crashed in late July after Reuters reported that the U.S. Justice Department had initiated a criminal probe over its experimental Alzheimer’s therapy, a claim company denied. Despite a ~31% selloff in 2022, SAVA shares have recovered since then, adding ~78% to strongly outperform the ~5% gain of the SPDR S&P Biotech ETF (XBI). The rally coincided with two recent insider purchases, including those from Directors Sanford Robertson and Barry Richard. Robertson, the principal of technology buyout fund Francisco Partners, bought 100K SAVA shares in August for over $2M to raise his stake by ~11%.

Seeking Alpha • Sep 03

Cassava Sciences Looks As Good Of A Purchase As Ever

Summary Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data. Another journal cleared the company of any wrongdoing. The SEC has officially ended any inquiries into the company. Introduction I give a strong buy rating to Cassava Sciences (SAVA). Throughout the drops, I have continued to add shares and DCA. In the past, I called Cassava Sciences the best risk to reward in the stock market, and when the price becomes even more attractive over noise, it makes it an even better risk to reward. Big pharma spent billions of dollars searching for drugs to help patients with Alzheimer's Disease ((AD)). Yet, a small former pain company out of Austin, Texas – a place not known as a biotech mecca – has released data that blows everybody else's products out of the water. Unlike its competitors' expensive, impractical IV solutions full of safety issues, Cassava Sciences' solution is a small pill without known safety concerns. From the graveyard of AD therapy has come life called Simufilam. Because of this unlikeliness, the company has been shorted down to pennies of its all-time highs achieved last summer. While shorting a highly hyped stock is usually a brilliant bet, based on looking at all claims for and against the company, I believe that Cassava Sciences has seemingly done the impossible. You can read my bullish public coverage going back well over a year on Seeking Alpha and my reasons for my strengthening belief below. Four Bullish Events Since We Last Spoke As stated by Peter Lynch, "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise." And buy the Cassava Sciences insiders have done. Since the last quarterly report, four insiders have purchased over $3 million in shares on the open market, including longtime Salesforce (CRM) board member and supporter of Neuroscience Sanford Robertson, increasing his share position by ~10% to push him past 1 million shares. In addition to the above buying, no insider has sold shares for years. Insiders have privileged information, and their moves speak volumes. These insiders are yelling very loudly as they try to get their hands on as many shares as possible. The last insider buy on the open market was September 24th, 2020, shortly before the stock rose in the summer of 2021 to over $100 and became the top performing stock of the year. Even more importantly, this was three months before the company announced its groundbreaking six-month OLE results. The company insiders likely had a closed buying period shortly after that purchase and at least through the data announcements of 2021. September 2020 was most likely the last time insiders had the chance to buy on the open market, considering we have not seen any buys between these two open market buys. One thing that undoubtedly strengthened the insiders' belief was when on August 3rd the company announced 12-month data for 100 patients from its phase 3 trials. While the second 50 cohort was admittedly not as good as the first 50, the second 50 was still very good. Highlights from the data are that 63% of patients improved cognition, a remarkable achievement considering that AD is a disease of continual decline. Additionally, another 21% of patients slowed less than five cognitive points, meaning that the drug was able to slow down the effects of AD. Overall, 84% of patients saw a positive impact from the drug. If the company is able to achieve a result anywhere close to this while the drug's safety profile remains impeccable, then I would be shocked if they were unable to secure approval. The 100 patient data further de-risks the stock by decreasing the chances of a phase 3 failure. In the middle of the frenzy of insider buyers, a surprise occurred when yet another scientific journal found no data manipulation in Cassava Science's scientific publications on Simufilam. The Journal of Prevention of Alzheimer's Disease ((JPAD)) is a positive step in the right direction while we wait for critical regulatory clearance from the City University of New York ((CUNY)). Many retail investors question the importance of CUNY, but that is because its importance is not for retail investors. Instead, its importance is for institutional investors. I speculate that this is the hold-up for many institutions purchasing the stock, resulting in very low institutional ownership. Institutions have to answer to their clients, and no matter how good the data for Cassava Sciences look, if an institution invested before a CUNY clearance and CUNY ruled against Cassava Sciences, then the institution would have some severe repercussions to face. While we are still waiting on CUNY, we have positive news that the SEC has concluded all its inquiries into the company. From SEC investigation expert John P Gavin from Disclosure Insight's work, we can tell that the SEC performed an extensive inquiry into Cassava Sciences, totaling 48 boxes of documents that did not end in any formal investigation. CEO Remi Barbier said the company gave "nearly 100,000 pages of documents to an alphabet soup of outside investigative agencies … [they have] yielded an important finding to date: there is no evidence of research misconduct." Commercially bought paper comes in 5000 pages for a box, but loose leaf paper fits much looser in a box. From my research, only about 2500 pieces of loose leaf paper can fit in a box, so the number of documents from this quote aligns with the 48-box comment from the SEC. Regardless of the amount, it is in the rearview mirror for the company. Events on the Horizon Before the end of the year, Cassava Sciences should release 12-month data for 200 patients from its OLE trial, which will further boost the odds of success in phase three trials if the data continues to be positive. Additionally, the company will release 12-month biomarker data for 25 patients, which will provide another validation for Cassava Sciences' data results. Something to remember is that Aduhelm from Biogen (BIIB) was approved based on biomarker data, not cognitive data. Looking ahead, mid-2023 should yield the results of the company's cognition maintenance study showing data from patients on the drug for 18 months and having the first placebo-controlled data. Finally, the company will have completed phase three trials in early to mid-2024, whose results will determine whether or not Simufilam gets approved. The coming two years will be exhilarating for Cassava Sciences' investors. Financials

Seeking Alpha • Aug 26

Cassava Sciences stock jumps 10% after director buys $860K shares

In a regulatory filing, Cassava Sciences (NASDAQ:SAVA) disclosed that its director Richard Barry bought 36.16K shares of common stock at $23.79 on Aug.23 for a total outlay of $860K. The move leaves Richard Barry with ownership of 186,159 shares. A quick look at the company's ownership structure: Shares of Cassava Sciences are up 10.37% afterhours at $30.11.

スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

過去の株価
現在の株価	US$1.31
52週高値	US$4.98
52週安値	US$1.16
ベータ	-0.76
1ヶ月の変化	-18.63%
3ヶ月変化	-39.35%
1年変化	-37.91%
3年間の変化	-94.44%
5年間の変化	-97.57%
IPOからの変化	-99.14%

	FLNA	US Pharmaceuticals	US 市場
7D	11.0%	5.0%	1.1%
1Y	-37.9%	44.3%	28.7%

FLNA volatility
FLNA Average Weekly Movement	9.5%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

FLNA 基礎統計学
時価総額	US$63.28m
収益（TTM）	-US$77.90m
売上高(TTM)	n/a

FLNA 損益計算書（TTM）
収益	US$0
売上原価	US$26.59m
売上総利益	-US$26.59m
その他の費用	US$51.31m
収益	-US$77.90m

一株当たり利益（EPS）	-1.61
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

データ	最終更新日（UTC時間）
企業分析	2026/05/24 15:05
終値	2026/05/22 00:00
収益	2026/03/31
年間収益	2025/12/31

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

アナリスト	機関
Gregory Fraser	BofA Global Research
Mayank Mamtani	B. Riley Securities, Inc.
Elemer Piros	Lucid Capital Markets

Filana Therapeutics（FLNA）株式概要

リスク分析

Filana Therapeutics, Inc. 競合他社

ImageneBio

Cingulate

Impact BioMedical

SCYNEXIS

価格と性能

最新ニュース

Filana Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Filana Therapeutics Announces Publication of Preclinical Simufilam Data in Epilepsia

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease

New minor risk - Market cap size

Cassava Sciences, Inc. Receives Formal Letter from FDA Confirming That the Proposed Clinical Trial Is on Full Clinical Hold Subject to the Company Providing Additional Pre-Clinical Data, and Modifying the Protocol Design

Recent updates

Filana Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Filana Therapeutics Announces Publication of Preclinical Simufilam Data in Epilepsia

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease

New minor risk - Market cap size

Cassava Sciences, Inc. Receives Formal Letter from FDA Confirming That the Proposed Clinical Trial Is on Full Clinical Hold Subject to the Company Providing Additional Pre-Clinical Data, and Modifying the Protocol Design

Cassava Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

CEO, President & Director recently bought US$202k worth of stock

Cassava Sciences, Inc. Appoints Dawn C. Bir to its Board of Directors

New minor risk - Share price stability

CEO, President & Director recently bought US$535k worth of stock

Cassava Sciences, Inc. Appoints Dr. Joseph Hulihan as Chief Medical Officer

Cassava Sciences, Inc. Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Sciences, Inc.(NasdaqCM:SAVA) dropped from Russell Small Cap Completeness Index

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Appoints Angélique Bordey as Senior Vice President, Neuroscience

Cassava Sciences, Inc. Announces Executive Changes

Price target decreased by 98% to US$2.00

Cassava Sciences, Inc., Annual General Meeting, May 23, 2025

Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data

Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value

Cassava Sciences Announces Reduction in Workforce

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Cassava Sciences, Inc

Chief Financial Officer notifies of intention to sell stock

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences: Turning The Corner Into A Brick Wall

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Independent Director exercised options to buy US$3.9m worth of stock.

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought US$308k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Founder exercised options and sold US$480k worth of stock

Lead Independent Director exercised options to buy US$259k worth of stock.

Independent Director recently bought US$2.3m worth of stock

Consensus EPS estimates upgraded to US$0.77 loss

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Forecast to breakeven in 2023